Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Humabs Biomed SA has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 2 distinct art units, indicating a broader docket with repeated assignments within the examination structure.
LY, KRISTINA ELISABETH is the busiest examiner, with 2 pending matters. That examiner is the clearest concentration point in the profile, so counsel should coordinate those matters while separately managing the remaining examiner and art-unit assignments.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LY, KRISTINA ELISABETH | 2 | 37.5% | +100.0% |
| GRIZER, CASSANDRA SENN | 1 | 70.0% | +48.0% |
| JADHAO, SAMADHAN JAISING | 1 | 46.2% | +47.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264408 | ANTIBODIES AGAINST RESPIRATORY SYNCYTIAL VIRUS, HUMAN METAPNEUMOVIRUS AND PNEUMONIA VIRUS OF MICE AND METHODS OF USING THE SAME | GRIZER, CASSANDRA SENN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002844 | ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND USES THEREOF | JADHAO, SAMADHAN JAISING | 16d overdue |
| 18264408 | ANTIBODIES AGAINST RESPIRATORY SYNCYTIAL VIRUS, HUMAN METAPNEUMOVIRUS AND PNEUMONIA VIRUS OF MICE AND METHODS OF USING THE SAME | GRIZER, CASSANDRA SENN | — |
| 18256419 | ANTIBODIES BINDING TO F-PROTEIN OF METAPNEUMOVIRUS AND USES THEREOF | LY, KRISTINA ELISABETH | — |
| 18253383 | ANTIBODIES AGAINST INFLUENZA A VIRUSES | LY, KRISTINA ELISABETH | — |
| Art Unit | Apps |
|---|---|
| 1672 | 2 |
| 1671 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264408 | ANTIBODIES AGAINST RESPIRATORY SYNCYTIAL VIRUS, HUMAN METAPNEUMOVIRUS AND PNEUMONIA VIRUS OF MICE AND METHODS OF USING THE SAME | GRIZER, CASSANDRA SENN | 1672 | §103§112 | Non-Final OA | — | Pending | Aug 04, 2023 |
| 18256419 | ANTIBODIES BINDING TO F-PROTEIN OF METAPNEUMOVIRUS AND USES THEREOF | LY, KRISTINA ELISABETH | 1671 | §112 | Final Rejection | — | Pending | Jun 07, 2023 |
| 18253383 | ANTIBODIES AGAINST INFLUENZA A VIRUSES | LY, KRISTINA ELISABETH | 1671 | §112Other | Final Rejection | — | Pending | May 17, 2023 |
| 18002844 | ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND USES THEREOF | JADHAO, SAMADHAN JAISING | 1672 | §103 | Non-Final OA | 16d overdue | Pending | Dec 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHumabs Biomed SA has 4 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Kristina Elisabeth Ly has the most, with 2 of Humabs Biomed SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
